Covis Pharma, current maker of the preterm birth drug Makena, has withdrawn it from the market after a US Food and Drug Administration (FDA) panel deemed it ineffective. Approved more than a ...

Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary. The ...

Specialist drug-maker Covis Pharma is having a rough time in the primary market, with lack of investor demand forcing it to reduce the size of a euro note, completely scrap a proposed dollar bond and ...